Cargando…

CD26/DPP4 as a Therapeutic Target in Nonalcoholic Steatohepatitis Associated Hepatocellular Carcinoma

SIMPLE SUMMARY: CD26/DPP4 has been reported to attenuate anticancer immunity via chemokine cleavage and to promote insulin resistance and inflammation in the liver and/or adipose tissue via dysregulation of macrophage M1/M2 polarization. These results suggest the promotive roles of CD26/DPP4 especia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishina, Sohji, Hino, Keisuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774170/ https://www.ncbi.nlm.nih.gov/pubmed/35053615 http://dx.doi.org/10.3390/cancers14020454

Ejemplares similares

Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice
por: Nishina, Sohji, et al.
Publicado: (2018)

Nonalcoholic steatohepatitis and hepatocellular carcinoma: Brazilian survey
por: Cotrim, Helma P., et al.
Publicado: (2016)

Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma: Brazilian Survey
por: Alves, Venancio Avancini Ferreira, et al.
Publicado: (2016)

Dipeptidyl peptidase-4 (DPP-4; CD26)
Publicado: (2013)

Serum Glycoprotein Markers in Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma
por: Ramachandran, Prasanna, et al.
Publicado: (2022)

Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma
por: Koo, Seo-Young, et al.
Publicado: (2020)

Nonalcoholic steatohepatitis and hepatocellular carcinoma: Beyond the boundaries of the liver
por: Gupta, Tarana
Publicado: (2022)

Soluble CD163 is a predictor of fibrosis and hepatocellular carcinoma development in nonalcoholic steatohepatitis
por: Kawanaka, Miwa, et al.
Publicado: (2023)

CD26/DPP-4 in Chronic Myeloid Leukemia
por: Sicuranza, Anna, et al.
Publicado: (2022)

Fibrosis-4 index is associated with the risk of hepatocellular carcinoma in patients with cirrhosis and nonalcoholic steatohepatitis
por: Albhaisi, Somaya, et al.
Publicado: (2023)

Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma
por: Kutlu, Ozlem, et al.
Publicado: (2018)

Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma
por: Peiseler, Moritz, et al.
Publicado: (2021)

Emerging Roles of T Cells in the Pathogenesis of Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma
por: Hirsova, Petra, et al.
Publicado: (2021)

Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma
por: Cernea, Simona, et al.
Publicado: (2023)

Resection of Nonalcoholic Steatohepatitis-Associated Hepatocellular Carcinoma: A Western Experience
por: Shrager, Brian, et al.
Publicado: (2012)

Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma
por: Wu, Jian
Publicado: (2016)

Type 1 interferon receptor in peripheral blood mononuclear cells may predict response to intra-arterial 5-fluorouracil + interferon therapy for advanced hepatocellular carcinoma
por: Tomiyama, Yasuyuki, et al.
Publicado: (2011)

Recent Insight into the Role of Fibrosis in Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma
por: Sircana, Antonio, et al.
Publicado: (2019)

Lymphatic Dysfunction as a Novel Therapeutic Target in Nonalcoholic Steatohepatitis
por: Jeong, Jain, et al.
Publicado: (2020)

Anti-CD122 antibody restores specific CD8(+) T cell response in nonalcoholic steatohepatitis and prevents hepatocellular carcinoma growth
por: Lacotte, Stéphanie, et al.
Publicado: (2023)

Repurposing drugs to target nonalcoholic steatohepatitis
por: Sookoian, Silvia, et al.
Publicado: (2019)

Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma
por: Takakura, Kazuki, et al.
Publicado: (2018)

Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway?
por: Ali, Mahmoud A, et al.
Publicado: (2017)

Smad Phospho-Isoforms for Hepatocellular Carcinoma Risk Assessment in Patients with Nonalcoholic Steatohepatitis
por: Suwa, Kanehiko, et al.
Publicado: (2020)

A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma
por: Tucker, Robin D., et al.
Publicado: (2019)

The Serine Protease CD26/DPP4 in Non-Transformed and Malignant T Cells
por: Chitadze, Guranda, et al.
Publicado: (2021)

Functional roles of CD26/DPP4 in bleomycin‐induced pulmonary fibrosis
por: Koyanagi, Yu, et al.
Publicado: (2023)

CD26/DPP-4: Type 2 Diabetes Drug Target with Potential Influence on Cancer Biology
por: Kawakita, Emi, et al.
Publicado: (2021)

Correction: Medaka as a model for human nonalcoholic steatohepatitis
por: Matsumoto, Toshihiko, et al.
Publicado: (2023)

Treatment of nonalcoholic steatohepatitis with vitamins E and C: a pilot study
por: Kawanaka, Miwa, et al.
Publicado: (2013)

Gemigliptin, a DPP4 inhibitor, ameliorates nonalcoholic steatohepatitis through AMP-activated protein kinase-independent and ULK1-mediated autophagy
por: Song, Youngmi, et al.
Publicado: (2023)

Oleate acid-stimulated HMMR expression by CEBPα is associated with nonalcoholic steatohepatitis and hepatocellular carcinoma
por: Zhang, Deyu, et al.
Publicado: (2020)

Bariatric Surgery Associates with Nonalcoholic Steatohepatitis/Hepatocellular Carcinoma Amelioration via SPP1 Suppression
por: Chen, Shuai, et al.
Publicado: (2022)

Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma
por: Kanda, Tatsuo, et al.
Publicado: (2020)

Apigenin directly interacts with and inhibits topoisomerase 1 to upregulate CD26/DPP4 on colorectal carcinoma cells
por: Fux, Julia E., et al.
Publicado: (2022)

Targeting of Secretory Proteins as a Therapeutic Strategy for Treatment of Nonalcoholic Steatohepatitis (NASH)
por: Kim, Kyeongjin, et al.
Publicado: (2020)

Targeting MRG15 for the treatment of nonalcoholic steatohepatitis
por: Zhang, Yao, et al.
Publicado: (2022)

A narrative review on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis versus hepatocellular carcinoma: do you mind?
por: Toman, Daniel, et al.
Publicado: (2022)

Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches
por: Kim, Kook Hwan, et al.
Publicado: (2018)

Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis
por: Yang, Rui-Xu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7tlpgs2qkj8jnqk9p83a59q9dp